Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May-Aug;25(2):327-331.
doi: 10.4103/0973-029X.325236. Epub 2021 Aug 31.

Secretory carcinoma of salivary gland - A systematic review of pediatric case reports and case series

V Vasanthi  1 , R Ramadoss  2
Affiliations
Review

Secretory carcinoma of salivary gland - A systematic review of pediatric case reports and case series

V Vasanthi et al. J Oral Maxillofac Pathol. 2021 May-Aug.

Abstract

Aim: Mammary analog secretory carcinoma (MASC) is a new pathological entity of salivary gland origin recognized as Secretory Carcinoma (SC) in the WHO 2017 classification. Pediatric cases of MASC were reviewed systematically from 2010 to 2019.

Materials and methods: Databases were searched from 2010 to 2019 for pediatric case reports and case series, excluding retrospective studies. A total of 12 manuscripts were reviewed for clinical, histological and immunohistochemical findings.

Results: A total of 13 pediatric cases (11 case reports and 1 case series of 2 cases) of MASC in pediatric patients were found. The youngest reported age was 5 years. The common site was parotid gland usually presenting as a slowly growing firm, painless mass.

Conclusion: MASC should be considered in the differential diagnosis of salivary gland tumors in pediatric population, especially from parotid gland. Extended research on such recent entities with more inputs from new cases reported in literature may outstretch the possibilities of therapeutic fusion inhibition in future.

Keywords: Mammary analog; pediatric case reports; pediatric case series; salivary gland; secretory carcinoma.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Data extraction as per PRISMA guidelines
See this image and copyright information in PMC

References

    1. Boon E, Valstar MH, van der Graaf WTA, Bloemena E, Willems SM, Meeuwis CA, et al. Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands. Oral Oncol. 2018;82:29–33. - PubMed
    1. Boliere C, Murphy J, Qaisi M, Manosca F, Fung H. Mammary analogue secretory carcinoma of the palate: Case report and review of the literature. Case Rep Dent. 2019:7416302. - PMC - PubMed
    1. Skálová A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: A hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599–608. - PubMed
    1. Balanzá R, Arrangoiz R, Cordera F, Muñoz M, Luque-de-León E, Moreno E, et al. Mammary analog secretory carcinoma of the parotid gland: A case report and literature review. Int J Surg Case Rep. 2015;16:187–91. - PMC - PubMed
    1. Salat H, Mumtaz R, Ikram M, Din NU. Mammary analogue secretory carcinoma of the parotid gland: A third world country perspective-a case series. Case Rep Otolaryngol. 2015:697254. - PMC - PubMed